Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Directorate Change

28 Jun 2019 07:00

RNS Number : 7219D
DeepMatter Group PLC
28 June 2019
 

28 June 2019

DeepMatter Group plc

("DeepMatter", the "Company" or the "Group")

 

Directorate Change

 

As previously announced, DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitizing chemistry, is pleased to confirm the appointment of Lauren Lees to the Board as Financial Director with immediate effect.

 

Lauren is a chartered accountant who qualified with Grant Thornton UK LLP and has been Financial Controller at the Company since October 2018, during which time she has played a significant role in the strategic and operational development of the Group. Previously, she was Financial Controller at BioOutsource Limited, a high growth start-up life science company which was acquired by Sartorius AG in 2015, and then rebranded as Sartorius Stedim BioOutsource Limited, serving on both the local management and strategy teams. Lauren takes over as Financial Director from Michael Bretherton who has stepped down with immediate effect.

 

Lauren Rachel Lees, aged 31, holds no other current directorships, nor has she held a directorship during the five years prior to her appointment. She holds no interest in ordinary shares of the Company. There are no further disclosures to be made in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented: 

 

"We are grateful for the significant contribution Michael has made to the business and wish him well in his future endeavours. We are also pleased to welcome Lauren to her new role as Financial Director. Her positive influence on not only the finance department, but also the broader Group so far has been significant, and we look forward to benefitting from her skills and experience further at Board level."

 

Ends

 

 

For further information:

 

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

Shore Capital (Nominated Adviser and Broker)

T: 020 7601 6100

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Susie Hudson

Jessica Joynson

 

T: 020 3405 0209

deepmatter@almapr.co.uk

 

About DeepMatter:

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUCAQUPBGAM
Date   Source Headline
28th Aug 20209:05 amRNSSecond Price Monitoring Extn
28th Aug 20209:00 amRNSPrice Monitoring Extension
19th Aug 20208:54 amRNSHolding(s) in Company
11th Aug 20204:13 pmRNSHolding(s) in Company
6th Aug 202012:30 pmRNSHolding(s) in Company
29th Jul 202012:16 pmRNSHolding(s) in Company
29th Jul 20209:45 amRNSHolding(s) in Company
29th Jul 20209:45 amRNSHolding(s) in Company
23rd Jul 20209:59 amRNSHolding(s) in Company
22nd Jul 20209:05 amRNSSecond Price Monitoring Extn
22nd Jul 20209:00 amRNSPrice Monitoring Extension
21st Jul 20205:11 pmRNSHolding(s) in Company
14th Jul 20207:00 amRNSResults of Placing
13th Jul 20207:00 amRNSPlacing and Subscription to raise £2.1 million
2nd Jul 20204:41 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20201:39 pmRNSResult of AGM and Directorate Change
4th Jun 20207:00 amRNSDigitalGlassware to Interface with Waters’ UNIFI
1st Jun 20204:41 pmRNSSecond Price Monitoring Extn
1st Jun 20204:36 pmRNSPrice Monitoring Extension
29th May 20207:00 amRNSFinal Results
26th May 20207:00 amRNSNotice of Results and Investor Presentation
11th May 202011:57 amRNSHolding(s) in Company
1st May 20208:21 amRNSHolding(s) in Company
28th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSContract with Cancer Research UK Beatson Institute
20th Feb 20207:00 amRNSCollaboration with the University of Nottingham
20th Feb 20207:00 amRNSCollaboration with the University of Nottingham
12th Feb 20207:00 amRNSDeepMatter collaborates with University of Leeds
24th Jan 20207:00 amRNSChange of Adviser
21st Jan 20206:10 pmRNSDirector/PDMR Shareholding
16th Dec 20197:00 amRNSDeepMatter Appoints Industry Advisors
9th Dec 20194:40 pmRNSSecond Price Monitoring Extn
9th Dec 20194:35 pmRNSPrice Monitoring Extension
9th Dec 201911:05 amRNSSecond Price Monitoring Extn
9th Dec 201911:00 amRNSPrice Monitoring Extension
9th Dec 20197:00 amRNSDeepMatter collaboration with AstraZeneca
19th Sep 20197:00 amRNSInterim Results
12th Aug 20197:00 amRNSLaunch of DigitalGlassware Online Portal
8th Aug 20197:00 amRNSFirst revenues for DigitalGlassware
3rd Jul 20192:55 pmRNSChange of Registered Address
28th Jun 20197:00 amRNSDirectorate Change
21st Jun 201912:34 pmRNSChange of Adviser
3rd Jun 20193:41 pmRNSHolding(s) in Company
22nd May 201911:19 amRNSResult of AGM
12th Apr 20197:01 amRNSBoard Changes & Appointments to Advisory Committee
12th Apr 20197:00 amRNSFinal Results
11th Apr 20195:12 pmRNSHolding(s) in Company
10th Apr 201912:58 pmRNSHolding(s) in Company
4th Apr 20193:57 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.